Movement Disorders

Papers
(The H4-Index of Movement Disorders is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
The FDA Has Ended Required Blood Monitoring for Clozapine Use—Will This Impact the Management of Parkinson's Disease Psychosis?615
258
The Pattern and Stages of Atrophy in Spinocerebellar Ataxia Type 2: Volumetrics from ENIGMA‐Ataxia197
May Infographic146
Movement Disorders: Volume 40, Number 6, June 2025133
Motor Cortex Disinhibition Correlates with Olfactory Dysfunction in Parkinson's Disease112
Movement Disorders: Volume 40, Number 2, February 2025104
John Michael Walshe (April 24, 1920–October 14, 2022)101
Issue Information97
In Memoriam Mahlon R. DeLong (1938–2024)97
Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials96
The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease90
Stability of Mosaic Divergent Repeat Interruptions in X‐Linked Dystonia‐Parkinsonism89
Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters86
Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals85
Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy80
Safety, Tolerability, Pharmacokinetics, and Brain Target Occupancy of the OGA Inhibitor ASN90 in H78
Early Changes in Striatal Activity and Motor Kinematics in a Huntington's Disease Mouse Model77
Biallelic Variants in SLC27A3 Cause a Complex Form of Neurodegeneration with Brain Iron Accumulati73
Fixel‐Based Analysis Reveals Whole‐Brain White Matter Abnormalities in Cervical Dystonia70
Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy70
α‐Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid‐Binding Property69
The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure68
Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism68
A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease65
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers63
Bidirectional Transcription at the PPP2R2B Gene Locus in Spinocerebellar Ataxia Type 1262
The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?60
Substantia Nigra Elasticity Measurement Using Transcranial Shear Wave Elastography: A Potential Biomarker for Parkinson's Disease59
Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation58
Brain–Computer Interface Improves Symptoms of Isolated Focal Laryngeal Dystonia: A Single‐Blind Study57
Reply to: “Early Indian Age at Onset of Parkinson's: A Case for a Gene‐Environment Lens”56
56
55
Functional Movement Disorders and Drug‐Induced Movement Disorders54
The Lows of High Reward: Choking Under Pressure53
Obituary for Jan O. Aasly (1950–2022)53
Movement Disorders: Volume 37, Number 9, September 202253
Author Index52
Reply to: “An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis”51
Thank you to Reviewers 202251
In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN‐Related Parkinson's Disease49
Issue Information48
Central Involvement in Pure Autonomic Failure: Insights from Neuromelanin‐Sensitive Magnetic Resonance Imaging and 18F‐Fluorodopa‐Positron Emission Tomography48
Reply to: “Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders: More Common than Expected”48
Novel In‐Frame FGF14 Deletion Causes Spinocerebellar Ataxia Type 27A: Clinical Response to Deep Brain Stimulation and 4‐Aminopyridine46
0.077097177505493